PCOL2605 Lecture Notes - Lecture 4: Hoffmann-La Roche, Drug Discovery, Pharmaceutical Industry
23 Oct 2018
School
Department
Course
Professor
Document Summary
Research based pharmaceutical companies spend about 20% of their sales on research and development. This % is significantly higher than in most other industries. Since 1980 us pharma companies have doubled spending on r+d every 5 years. Despite these expenditures there has been a steady decline in the number of drugs introduced each year into human therapy. Innovation deficient coined in 1996 by jurgen drews, president of research at hoffmann la roche. Reasons for the innovation deficit: increased demand on safety for drugs. The average number of clinical trials per new drug application (nda) increased from 30 in the 70s to 40 in the 80s, to 70 in the 90s. The increased demand on safety is also reflected in a prolonged duration of the drug development process. In the 60s, total development time was 8. 1 years. Currently ~16 yrs: low hanging fruit have been picked, a new drug today costs ~880 mil and takes 15-16 yrs to develop.
